

June 29, 2022

FUNDING AND COMMERCIALIZATION RESOURCES FOR SMALL BUSINESSES

MICHAEL WEINGARTEN
JONATHAN FRANCA-KOH
SBIR DEVELOPMENT CENTER
NATIONAL CANCER INSTITUTE

SBIR

DEVELOPMENT CENTER



TODAY'S SPEAKERS



Michael Weingarten
Director



Jonathan Franca-Koh
Program Director

SBIR & STTR Overview

SBIR PROGRAMS

11 Federal Agencies

Department of Defense

Department of Health and Human Services

Department of Energy

National Science Foundation

National Aeronautics and Space Administration

Department of Agriculture

Department of Homeland Security

Department of Commerce


Department of Transportation

Department of Education

Environmental Protection Agency



27 INSTITUTES & CENTERS AT THE NIH




CONGRESSIONALLY MANDATED PROGRAM

Set Aside for FY20

SBIR SMALL BUSINESS INNOVATION RESEARCH	Set-aside program for small business concerns to engage in Federal R&D with the potential for commercialization <i>Federal agencies with an extramural R&D budget > \$100M</i>	\$157M (3.2%)
STTR SMALL BUSINESS TECHNOLOGY TRANSFER	Set-aside program to facilitate cooperative R&D between small business concerns and U.S. research institutions with the potential for commercialization <i>Federal agencies with an extramural R&D budget > \$1B</i>	\$22M (0.45%)
Total		\$1.18B for NIH \$179M for NCI

NCI SBIR VISION & MISSION



NCI SBIR supports small businesses across the US to develop innovative cancer technologies with the strong potential to help all people live longer, healthier lives.



Create an ecosystem that propels innovators to find solutions for cancer.



NCI SBIR makes entrepreneurship possible for all.

NCI SBIR CORE ACTIVITIES



CENTRAL OVERSIGHT

Administer all 400+ SBIR/STTR awards at the NCI



GUIDANCE

Help prepare for application, resubmission, & discuss funding options



OUTREACH

Attend conferences/workshops & visit organizations/universities to raise awareness of the program



FUNDING

Seed emerging technology areas through targeted grant & contract funding opportunities



NETWORKING

Maintain a network of investors and facilitate connections between portfolio companies & investors/strategic partners




TRAINING

Provide entrepreneurship training on key topics such as IP, regulatory strategy, & how to build a strong team

NCI SBIR/STTR PORTFOLIO

- \$179M in FY2020 for SBIR/STTR awards
- 86% Grants and 14% Contracts in FY2020
- Oversee 475+ active SBIR/STTR awards
- Fund companies in preclinical and clinical stages

What We Fund



ELIGIBILITY



Applicant must
be a Small
Business
Concern (SBC)



Organized
for-profit U.S.
business
(based in the
U.S. and work
performed in
the U.S.)



500 or fewer
employees,
including
affiliates



> 50% U.S.- owned by individuals and
independently operated

OR

> 50% owned & controlled by another (one) business
concern that is > 50% owned & controlled by one or more
individuals

OR

> 50% owned by multiple venture capital operating
companies, hedge funds, private equity firms, or any
combination of these (**SBIR ONLY**)

WHY SEEK SBIR FUNDING?



Provides seed funding for innovative technology development //

Not a Loan

No repayment is required
Doesn't impact stock or shares in any way (i.e., non-dilutive.)



Intellectual property rights retained by the small business //

NIH does not request intellectual property for the SBIR- or STTR-funded technologies.



Provides recognition, verification, and visibility //

Every application is rigorously assessed by NIH Peer Review system.



Helps provide leverage in attracting additional funding or support //



In addition to funding, we provide commercialization resources to help advance your project.

CRITICAL DIFFERENCES


SBIR		STTR
<u>Permits</u> research institution partners (e.g., universities)	PARTNERSHIP	<u>Requires</u> research institution partners (e.g., universities)
Small business may outsource ~33% of Phase I activities and 50% of Phase II activities	DIVISION OF LABOR	Minimum 40% of the work should be conducted by the small business (for profit), and minimum of 30% by a U.S. research institution (non-profit)
The PD/PI's primary employment (i.e., >50%) MUST be with the SBC for the duration of the project period	PI INVOLVEMENT	PI primary employment not stipulated (min.10% effort to project)

The award is ALWAYS made to the small business concern.

FUNDING MECHANISMS



THREE-PHASE PROGRAM



FUNDING OPPORTUNITIES

FUNDING OPPORTUNITIES

TITLE	SBIR FOA	STTR FOA	RECEIPT DATES
Omnibus Solicitation	PA-20-260 (General) PA-20-262 (Clinical Trial)	PA-20-265 (General) PA-20-261 (Clinical Trial)	Standard Receipt Dates April 5; January 5; September 5
SBIR Technology Transfer (technology transfer out of NIH intramural labs)	PA-18-705 (SBIR only)	No STTR	
Illuminating the Druggable Genome (IDG)	PA-19-034	PA-19-033	
Development of Highly Innovative Tools and Technology for Analysis of Single Cells	PA-20-047	PA-20-025	
SBIR IMAT (Innovative Molecular Analysis Technology) Development	PAR-18-303 (SBIR only)	No STTR	
Contract Solicitation	PHS 2022-1 (SBIR only)	No STTR	~ October 2021
Phase IIB Bridge Award	RFA-CA-21-036	Same as SBIR	~ August 2021

FY23 NIH/NCI CONTRACT TOPICS

Solicitation will be available here Summer 2022:


<https://sbir.cancer.gov/funding/contracts/currentcontracts>

Topic Title	Goal
Development of Senotherapeutic Agents for Cancer Treatment	Support the basic and pre-clinical development of senotherapeutic agents for use in research, neoadjuvant, adjuvant, or combination cancer therapy.
Non-invasive Device Technology Research & Development for Chemotherapy-induced Peripheral Neuropathy Management	Advance the development of innovative non-invasive device technologies to provide effective mitigation of CIPN in a noninvasive, cost-effective, accessible manner in the home-care setting.
Wearable Devices for Dosimetry of Radiopharmaceutical Therapy	Develop wearable technologies (e.g., dosimetry sensor-incorporated clothing) to allow radiopharmaceutical therapy dose to be continuously measured providing rich, time-based dose data for RPT agents that can be correlated with the patient's anatomy.
Wearable Technologies to Facilitate Remote Monitoring of Cancer Patients Following Treatment	Improve the availability of new and/or better remote monitoring tools for patients and their clinical care teams during sensitive periods of treatment with a view to improved health-related Quality of Life and reduced costs associated with further hospital visits.
Technology Platforms for Circulating Tumor-Macrophage Hybrid Cells	Support the development of platforms to isolate, enrich, enumerate, and identify the cTMHCs in blood from cancer patients or animal models of cancer. This contract topic aims to enable thorough understanding of the biology of THMCs in metastasis and provide a novel means to remotely monitor cancer progression and metastasis.
Rapid and Affordable Point-of-Care HPV Diagnostics for Cervical Cancer Control	Advance the development of new alternatives for HPV testing to the market that are both in a form factor as well as price point that will enable self-testing programs to be established globally.
Translation of Novel Cancer-Specific Imaging Agents and Techniques to Mediate Successful Image-Guided Cancer Interventions	Support the translation of novel activatable agents and/or techniques for sensitive cancer detection in human subjects. Ideally, this would translate existing pre-clinical successes with activatable diagnostic probes to clinical tools that can detect small tumor cell clusters (~1mm ³ in volume) via imaging.
Digital Tools to Integrate Cancer Prevention Within Primary Care	Develop a digital platform that provides PCPs with validated cancer risk assessment tools, cancer prevention guidelines, and clinical recommendations based on a patient's risk factors to discuss with their patients.
Software to Evaluate Artificial Intelligence/Machine Learning Medical Devices in Oncology Settings	Stimulate the participation of small businesses in FDA's Medical Device Development Tool (MDDT) program to develop software tools for evaluating and monitoring AI/ML devices in oncology settings.

GRANTS VS. CONTRACTS

GRANTS		CONTRACTS
Investigator-defined within the mission of NIH	Scope of the proposal	Defined by the NIH (focused)
NIH Center for Scientific Review (CSR)	Peer Review Locus	NCI DEA (target 50% business reviewers)
May speak with any Program Officer	Questions	<u>MUST</u> contact the contracting officer
3 times/year for Omnibus	Receipt Dates	Only ONCE per year
NO	Set-aside of funds for particular areas?	YES
Based on score during peer review	Basis for Award	If proposal scores well during peer review, must then negotiate to finalize deliverables with NIH
One final report (Phase I); Annual reports (Phase II)	Reporting	Kick-off presentation, quarterly progress & final reports

SMALL BUSINESS TRANSITION GRANT



RELEASED: NOVEMBER 20, 2020

APPLICATIONS DUE: MARCH 24, 2021 - *Received 16 applications*

AWARDS EXPECTED: FALL 2021


SMALL BUSINESS TRANSITION GRANT



Funding support for early-career academic entrepreneurs (e.g., Postdocs) to advance innovative technologies from the academic lab bench to the clinic.

- First of its kind of funding opportunity at the NIH and the NCI.
- \$2.4M Fast-track award for early-career entrepreneurs that combines a Phase I STTR & Phase II SBIR.
- Mentoring team is key component of the award – critical for successful transition to product development.
- Created to directly address gap reported by academic entrepreneurs at NCI-designated Cancer Centers.
- 4 awards made in FY2022.

SMALL BUSINESS CONCEPT AWARD



Six awards made in first year of the program with the fastest turn-around time of 5.5 - 6 months

- Phase I SBIR Contract Funding (\$300K)
- Focus is on innovation
- Disruptive technologies to address rare and pediatric cancer
- Short applications (~20 pages vs. 50)
- Special review criteria with focus on innovation
- Fund experiments to de-risk early-stage technologies
- Make awards rapidly (within six months)
- Awardees are expected to enroll in the NIH I-Corps Program
- Receipt Date: August 22, 2022
- Solicitation: [75N91022R00006](#)

PHASE IIB BRIDGE AWARD

[RFA-CA-20-033](#)



- Provides up to \$4M in additional funding over 2-3 years
- Technology validation and clinical translation
- Open to Phase II awardees from *any Federal agency* with projects relevant to NCI mission
- Accelerates commercialization by incentivizing partnerships with third-party investors & strategic partners earlier in the development process
- Competitive preference and funding priority to applicants that can raise substantial third-party funds (i.e., $\geq 1:1$ match)

Bridge Award: Purpose and Objectives



Milestones

Enable awardees to accomplish critical milestones that accelerate and improve the probability of commercialization by providing continued funding to companies that recently completed Phase II SBIR or STTR project



Partnerships

Promote partnerships between awardees and key/strategic partners to facilitate and accelerate the capital-intensive steps that are required for commercialization



Investment

Leverage federal funding to attract private investment that equals or exceeds NCI funds

Awardees are required to raise matching funds


Snapshot of Bridge Awards to Date



- 46 Awards
- 2-6 awards per year
- \$121 NCI Funding
- 4:1 Matching Funds



• Project types



• 16 Products Launched



APPLICATION TIPS

FROM IDEA TO AWARD...



GETTING STARTED



Read the solicitation & SF424 carefully to understand the requirements.

<https://grants.nih.gov/grants/how-to-apply-application-guide/forms-f/sbir-sttr-forms-f.pdf>



Review similar, currently-funded NIH SBIR/STTR projects.

<https://projectreporter.nih.gov/reporter.cfm>



Look at some sample applications.

<https://www.niaid.nih.gov/grants-contracts/sample-applications#r43r44>



TIP # 1

START EARLY



START EARLY

- **Strong proposals take time to develop**
 - Refining your product
 - Gain access to equipment, facilities, other resources
 - Assemble a strong scientific team
 - Obtain letters of support from collaborators
- **Complete the administrative registrations**
 - Five Required registrations (<https://sbir.nih.gov/infographic>)
 - Send specific aims to Program at least a month before




TIP # 2

FOCUS ON THE PRODUCT




FOCUS ON THE PRODUCT

ACADEMIC GRANT



SBIR/STTR GRANT




REFINE YOUR PRODUCT VISION

- **Start informal discussions to clarify the product vision**
 - Technical experts, potential customers, investors, commercialization partners, and other stakeholders
- **Seek help from others with experience and insights**
 - Current/prior SBIR grantees
 - Academic collaborators with grant writing experience
 - Professional grant writers*
 - **Engage with SBIR program staff for the most up-to-date information on agency priorities, current NIH policies, etc.**
- **Before you Apply**
 - Review similar, currently-funded NIH SBIR/STTR projects <https://projectreporter.nih.gov/reporter.cfm>

TIP # 3

**DISCUSS YOUR APPLICATION
WITH PROGRAM DIRECTOR**



REACH OUT TO AN NCI SBIR PROGRAM DIRECTOR



Michael Weingarten, MA
Director
NCI SBIR Development Center

Contact us to get started!
Send your Specific Aims page to ncisbir@mail.nih.gov and we will help you set up a call with one of our program directors!



Greg Evans, PhD
Lead Program Director
Cancer Biology, E-Health, Epidemiology, Research Tools



Christie Canaria, PhD
Program Director
Cancer/Biological Imaging, Research Tools, Devices, I-Corps at NIH



Jian Lou, PhD
Program Director
In-Vitro Diagnostics, Theranostics, early-stage drug development, Bioinformatics, Investor Initiatives



William Bozza, PhD
Program Director
Biologics, Protein Therapeutics, Regulatory (CMC)



Deepa Narayanan, MS
Lead Program Director
Imaging, Clinical Trials, Radiation Therapy, Investor Initiatives



Nancy Kamei, PharmD, MBA
Program Director
Cancer Therapeutics



Monique Pond, PhD
Program Director
Biologics, Small Molecules, Therapeutic Devices, Digital Health, Regulatory Resources



Patricia Weber, DrPH
Program Director
Digital Health, Therapeutics, Biologics, Resources Workshop



Kory Hallett, PhD
Lead Program Director
Monoclonal Antibodies, Immunotherapy, Biologics, and Program Analysis



Jonathan Franca-Koh, PhD, MBA
Program Director
Cancer Biology, Biologics, Small Molecules, Cell Based Therapies, Phase IIb Bridge




Amir Rahbar, PhD, MBA
Program Director
In-Vitro Diagnostics, Biologics, Therapeutics, Proteomics



Ming Zhao, PhD
Program Director
Cancer Diagnostics & Therapeutics, Cancer Control & Prevention, Molecular Imaging, Bioinformatics, Stem Cells

SPECIFIC AIMS PAGE

SPECIFIC AIMS



SPECIFIC AIMS PAGE ADVICE

The Aims Page

The specific aims page is a critical page in an SBIR/STTR application. The aims page should be treated as a stand-alone page from which a reviewer can gain a reasonable understanding of the project's critical components without reading any other parts of the application. Applicants are only allowed one page for their specific aims. Application are assigned to 3 or 4 primary reviewers who are responsible for initial scoring and acting as primary discussants during the larger peer review panel. Often the primary reviewers are the only members of the peer review panel to read the application in its entirety. For applications that are discussed, the final priority score will be set at discussion by a panel of 20+ peer reviewers. Many of the peer reviewers will likely only read the aims page of an application. Therefore, it is critical that the aims page clearly convey why this application should be selected out of the roughly thousand applications received by NCI SBIR the program annually.

The first half to two-thirds of the aims page should cover key background information. The background should clearly convey three things:

1. **The product.** A clear product description is critical to an SBIR application and is often a key difference separating an SBIR application from a basic science or discovery science application. SBIR grants are intended primarily for product development, whereas basic/discovery grants are primarily intended for the advancement of knowledge.
2. **The significance.** A problem/proposed solution format often works well to convey significance. If there is an unmet clinical need, it will help the application for this need to be clearly stated.
3. **The innovation.** How will the product change the current paradigm or practice? How will those affected by cancer benefit from this product being commercially available? The aims page should convey this information as well as provide some textual highlights of the preliminary data as supporting evidence that the product will perform as proposed.

The second half to one-third of the aims page should state your specific aims. An often-successful format for the aims is one in which a clear bulleted aims statement is made, followed by key assays and models proposed to complete each aim, with appropriate milestones. It is critical that each aim have clearly articulated success criteria. Whenever reasonable, the success criteria should be defined by quantitative metrics. However, in cases where only qualitative success criteria are appropriate, they should be clearly stated. For fast-track applications, a go/no-go decision at the end of the phase I component should be obvious.

A statement of next steps is often a nice way to wrap-up an aims page. A statement about what will be accomplished during phase II (for phase I applications) or after the award ends (for phase II applications) allows reviewers to judge if the aims will adequately prepare the project for the next step. A statement of next steps also provides an opportunity to show the reviewers that the company is focused on moving the product forward on a path to commercialization.

Overall, an SBIR application should focus on the product. Each section of the application should focus on how the proposed work will improve product commercialization. Successful SBIR/STTR applications clearly describe how the product will benefit a population affected by cancer, and identify the customer.

IMPORTANT: This guide page is meant to be used as advice for applicants and is not intended as program requirements. This advice page was developed based only on the opinions of several NCI SBIR Program Directors and successful SBIR awardees.

BACKGROUND:

Product
Innovation
Significance

AIMS:

Goals-based statements
Key assays and models
Quantitative milestones

CONTEXT:

These studies will get us to...
Next we will...
This data will be used for...

BUDGET LIMITS

	Standard Award	Hard Cap	Waiver Cap*
Phase I	\$150,000	\$275,766	NCI: \$400,000
Phase II	\$1.0M	~\$1.84M	NCI: \$2.0M

* Waiver cap is institute specific. The waiver cap listed above is for NCI only.

For the list of SBIR/STTR Waiver Topics for NCI, visit <https://bit.ly/19NCIwaiver>

BUDGET CONSIDERATIONS



Technical Assistance Money – \$6,500 for Phase I; \$50,000 for Phase II

SBIR guidelines:

- SBIR Phase I ($\geq 66\%$ of the work at company)
- SBIR Phase II ($\geq 50\%$ of the work at company)

STTR statutory requirement:

- STTR Phase I and Phase II ($\geq 40\%$ at the company, $\geq 30\%$ at research institution)

Work may be outsourced to a subcontractor(s); fee-for-service activities may count as direct costs

(discuss with NIH Program Director)


REVIEW CRITERIA



REJECTION - YOU ARE NOT ALONE!

- Remember the three Rs:
 - **Review** your summary statement
 - **Revise** your application
 - **Resubmit** and try again!
- Talk to your program officer.
We are here to help!

FUNDING SUCCESS RATE (FY11-15)



SUCCESS STORY: IMMUNOMEDICS



Trodelvy

(Sacituzumab Govitecan-hziy)

Antibody drug conjugate that is directed against Trop-2, a cell-surface protein expressed in many solid cancers.



2012

Immunomedics received SBIR award and used it to fund the first in-human trial of Trodelvy.



April 2020

FDA approved Trodelvy for treatment of Triple Negative Breast Cancer.




September 2020

Gilead agreed to acquire Immunomedics for **~\$21 billion**

ASSISTANCE and INITIATIVES

NCI SBIR ASSISTANCE



<https://sbir.cancer.gov/resources>

NIH APPLICANT ASSISTANCE PROGRAM

AAP is a **FREE** Application preparation **ASSISTANCE** program that is **10 weeks** in length.

PROGRAM GOAL

Provide a **mentor** for applicants with great technology, but little NIH experience and limited NIH experience in their network.

APPLICATION PERIOD

Check back in summer for new solicitation

<https://sbir.cancer.gov/aap>



AAP PROVIDES ✓	AAP DOES NOT PROVIDE ✕
Phase I SBIR/STTR application preparation support and review	Grant writer
Specific Aims page review and advice	Research plan development
Submission process coaching	Small business registration or NIH application submission services

AAP ELIGIBILITY

- **Simple eligibility criteria:**
 - **No previous NIH SBIR/STTR awards granted**
- **Particularly interested in applicants by individuals currently underrepresented in the biosciences** (not a requirement for program)
 - **Women-owned / Run businesses**
 - **Minority-owned / Run businesses**
 - **Small Businesses operating in an underrepresented (IDeA) state**

I-CORPS AT NIH



- **Funding Opportunity Announcement (FOA):** PAR-22-073
(next receipt date: November 15, 2022)
- Intensive **Entrepreneurial Immersion** course aimed at providing teams with skills and strategies to reduce commercialization risk
- Curriculum emphasizes **Reaching out to Customers** to test hypotheses about the market(s) for the technology
- Teams are expected to conduct over **100 interviews** in 8 weeks
- Format is focused on **Experiential Learning**
- NCI SBIR designed, launched, and manages the program for NIH
- Open to Phase I SBIR/STTR awardees from 24 Institutes at NIH and CDC

More information: <https://sbir.cancer.gov/icorps>

INVESTOR INITIATIVES PROGRAM



INVESTOR REVIEW //

Current & recent awardees can apply (~100/year)

Reviewed by pharma/MedTech & venture partners (e.g., BMS, Eli Lilly, OrbiMed, RA Capital)

ALL applicants receive constructive reviewer feedback



FUNDING SUPPORT TO PITCH //

NCI matches 25-30 companies with stage and technology appropriate events

Assists with presentation fees for one individual

NCI or Pharma managed company showcases



MENTORING & PITCH COACHING //

Selected companies receive coaching, give pitches at investor forums and conferences, and meet one-on-one with investor attendees



DIRECT INTRODUCTION TO INVESTORS //

Develop a wide network of investor/strategic partners

Companies are profiled in an investor-oriented booklet shared via newsletters and email


Direct introductions to SBIR awardees in NCI SBIR portfolio

Investor Initiatives Mini-Review in *Clinical and Translational Science*: <https://bit.ly/3vfLTwB>

TRECS WORKSHOP

NCI SBIR Workshop on T^ranslational R^esources to Eⁿhance C^ommercialization S^uccess

- Open to active awardees
- Speakers from FDA, CMS, NSF, pharma, med-tech, VCs and across NIH
- Panels on other sources of federal funding, resources & collaborative programs at NIH, and unique life science investment organizations
- 300+ One-on-one meetings with program directors and speakers
- Networking and Brainstorm sessions with other SBIR peers and NIH staff
- Next workshop – 2023



More information: <https://sbir.cancer.gov/programseducation/TRECS2021>

PLAN WEBINAR SERIES

Peer Learning and Networking (PLAN) Webinar Series

<https://sbir.cancer.gov/programseducation/plan>

Topics:

- ☐ How to Write a Good Specific Aims Page
- ☐ Spotlight Video: Small Business Transition Grant (SBTG)
- ☐ Implementing a Quality Management System (QMS)
- ☐ Spotlight Video: Top Takeaways on How to Set Up a Small Business
- ☐ Keys to a Successful IND Submission
- ☐ Spotlight Video: CARE Success Stories



Part I. Presentation

Watch pre-recorded panelist presentation on [the PLAN webpage](#) prior to joining the webinar and write down your questions.



Part II. Panel Session

Attend real-time panel session and ask your questions to the panelist and/or the moderating NCI SBIR program director.

PLAN WEBINAR SERIES

Peer Learning and Networking (PLAN) Webinar Series

<https://sbir.cancer.gov/programseducation/plan>

Topics:

- ❑ How to Write a Good Specific Aims Page
- ❑ Spotlight Video: Small Business Transition Grant (SBTG)
- ❑ Implementing a Quality Management System (QMS)
- ❑ Spotlight Video: Top Takeaways on How to Set Up a Small Business
- ❑ Keys to a Successful IND Submission
- ❑ Spotlight Video: CARE Success Stories

Therapeutics - Click video if interested in:

- Time budgeting
- Addressing competitive landscape
- Specific features for therapeutics
- Quantitative milestones
- Considerations when resubmitting your application



Diagnostics - Click video if interested in:

- Differentiating between SBIR and traditional academic grants
- Highlighting innovation
- Specific features for diagnostics
- Quantitative milestones



Digital Health - Click video if interested in:

- Highlighting significance and clinical impact
- Specific features for digital health
- Quantitative milestones
- Considerations for fast-track applications



Devices - Click video if interested in:

- Getting started
- Providing sufficient detail
- Specific features for devices
- Quantitative milestones
- Considerations for Phase 2 applications



EXECUTIVE ROUNDTABLE

- Platform for founders/CEOs/other C-Level Executives of NCI SBIR-funded startups to mentor and advise each other on real-life startup issues.
- 3 cohorts ongoing
- 2-3 hours once every 2 months



- Applications open later in 2022
- Technology or indication focus



- Networking
- Ongoing Mentoring & Advice
- Potential Partnerships



- Currently virtual due to COVID-19



- C-Level Executives of all awardees
- 10-12 participants per cohort

CONNECTING AWARDEES WITH REGULATORY EXPERTS (CARE)

The CARE Program supports awardee interactions with FDA and encourages communication with regulators early on in the technology development process

- Program to encourage early communication between small businesses and FDA
- New cohort in spring each year – stay tuned for 2023 application date!

CARE Program



- Educational presentations with speakers from CBER, CDER, and CDRH
- Recordings available from Spring 2021 [FDA Workshop for Oncology Start-ups](#)
- Stay tuned for future workshops!

Workshops



- <https://sbir.cancer.gov/resources/fda-resources>
- Resources webpage of key guidance documents applicable to small businesses
- Curated list of links to FDA educational webinars

NCI SBIR Website



EVENTS

Learn about our funding opportunities and resources from NCI SBIR program directors!

- **NCI SBIR Monthly Office Hour**
 - 3rd Friday of each month
 - A great opportunity to connect one-on-one with an NCI SBIR program director
 - Sign up and send your 1-page technology summary to Bryce Geiling (bryce.geiling@nih.gov)
- **Upcoming events**
 - Events are listed on NCI SBIR Events Page: <https://sbir.cancer.gov/newsevents/events>
 - Sign up for e-newsletter for the latest update: <https://sbir.cancer.gov/emailsignup>



GET IN TOUCH WITH US!

- CONTACT NCI SBIR PROGRAM BEFORE YOU APPLY.

- SEND US YOUR SPECIFIC AIMS PAGE.

- Web: <https://sbir.cancer.gov>
Email: ncisbir@mail.nih.gov
Twitter: @NCISBIR
LinkedIn: <http://bit.ly/ncisbirlinkedin>

SBIR
DEVELOPMENT CENTER

The screenshot shows the homepage of the National Cancer Institute SBIR Development Center. At the top, the NIH logo and the text 'NATIONAL CANCER INSTITUTE SBIR Development Center' are visible. Social media icons for Twitter, LinkedIn, and Facebook are in the top right corner. A search bar is located below the header. The main navigation menu includes links for HOME, ABOUT, FUNDING, PORTFOLIO, PROGRAMS & EDUCATION, RESOURCES, and NEWS & EVENTS. A large banner image shows a scientist in a lab coat working with laboratory equipment, with the text 'NCI SBIR provides funding, mentoring & networking assistance for small businesses with next-generation cancer technologies.' Below the banner, there are several content sections. The first section is titled 'NCI Funding during the COVID-19 Public Health Emergency' and contains text about the impact of the emergency and links to notices and updates. The second section is titled 'What are the NCI SBIR & STTR Programs?' and describes the programs as sources of early stage technology financing. The third section is titled 'Resources For' and is partially visible. On the right side, there is a 'Sign up' section with a text input field for an email address and a 'Submit' button. Below that is a 'Latest Announcements' section with a link to a 'New Supplement for Technologies Adapted for COVID-19'.

NIH NATIONAL CANCER INSTITUTE SBIR Development Center

Search...

HOME ABOUT FUNDING PORTFOLIO PROGRAMS & EDUCATION RESOURCES NEWS & EVENTS

NCI SBIR provides funding, mentoring & networking assistance for small businesses with next-generation cancer technologies.

NCI Funding during the COVID-19 Public Health Emergency

Due to the potential impact of the declared public health emergency caused by COVID-19, the NIH has issued multiple guide notices, including notice on late applications. If your business is affected by COVID-19, check the list of available measures on our [Notices Page](#).

For updates on NCI extramural funding activities, please check [NCI Director Dr. Norman E. Sharpless' post](#) on the NCI Bottom Line blog.

What are the NCI SBIR & STTR Programs?

The SBIR & STTR Programs are one of the largest sources of early stage technology financing in the United States. We welcome entrepreneurs and small business leaders to this website to explore grant and contract funding opportunities.

[Learn more about the programs >](#)

Resources For

Sign up

Sign up for the latest funding opportunities and events information from NCI SBIR Development Center.

Email:

Submit

Latest Announcements

[New Supplement for Technologies Adapted for COVID-19](#)

The NCI SBIR Development Center is issuing a [Notice of Special Interest \(NOSI\)](#) to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for COVID-19 (COVID-19) T1

THANK YOU

CONTACT INFO

NCI SBIR DEVELOPMENT CENTER

ncisbir@mail.nih.gov

240.276.5300

